Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Program Description

Hyperglycemia is a common adverse effect of targeted PI3K and AKT inhibitors in breast cancer and requires a multidisciplinary approach to management. At this intersection of oncology and endocrinology, effective care requires the expertise of oncologists to manage the primary cancer treatment and pharmacists to navigate the nuanced drug interactions and select appropriate antihyperglycemic agents that do not compromise anticancer efficacy. In this panel discussion, experts will provide a concise review of risk factors and prevention strategies, providing a foundation for a deeper discussion on implementation and actionable, real-world solutions within care teams. The core of this program will be dedicated to pharmacist-led interventions, where panelists will share their experiences and successes in leveraging team-based care to prevent treatment-induced hyperglycemia. The discussion will cover crucial topics such as patient monitoring, the nuances of selecting appropriate antihyperglycemic therapies, and strategies for navigating the challenges of multidisciplinary management. By highlighting successful models, best practices, and protocols for monitoring and management, this panel will equip oncology pharmacists to take a leadership role in developing and implementing institutional guidelines, ultimately improving patient outcomes and continuity of care for those receiving PI3K and AKT inhibitor therapies.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine pharmacist-led interventions for hyperglycemia management, emphasizing clinical opportunities in patient monitoring, therapy selection, and interdisciplinary collaboration
• Determine potential solutions to challenges in selecting antihyperglycemic therapies for patients treated with PI3K/AKT inhibitors
• Investigate pharmacist-integrated models and protocols for hyperglycemia management, including contributions to clinical guidelines and best practice implementation